BioMimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment™ Bone Graft

Posted on | November 4, 2009 | No Comments

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.

 

http://ow.ly/zlCi

Comments

Search

Search for:

Spine Blogger

• Synthes Continues to Grow, but, Spine is Sucking Wind!!!!
• Once again, XLIFTS NuVasive!
• FDA Approves Amplify in 6 to 5 Vote

MedPageToday

• Joint Replacement Registry Improves Quality of Care
• Similar Results with Early, Delayed ACL Surgery
• WFH: Acupuncture Eases Pain in Hemophilia Patients

Orthopedics This Week

• The Storm Clears for Medtronic
• Two Awards for Dr. Champ Baker
• Synthes 2Q10 Sales Rise 7.4%
• NuVasive: Tale of Two Markets
• Orthofix Continues Turnaround

Hip Resurfacing News

• Daniel Fox Bilateral Hip Resurfacing Dr. Barrack 2009/2010
• Sandy Hip Resurfacing with Dr. Engh 2010
• Mike Carrol Hip Resurfacing with Dr. Schmalzried 2004

Blogroll

• AAOS
• eOrthopod
• HealthPoint Capital Research
• MCRA Resource Center
• Medical Device Guru
• OPNews
• Orthopedics This Week
• OrthoSpineNews
• OrthoWorld
• WSJ Orthopedics Search

Meta

• Register
• Log in
• Entries RSS
• Comments RSS
• WordPress.org
• Twitter RSS